Elevated concentrations of 15-deoxy-Δ12,14 -prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor γ-inducing drugs

Liver International

Volumn 29, Issue 5, 2009, Pages 730-735

  Gressner, Olav A ^a   Gao, Chunfang ^b   Rehbein, Katharina ^a   Lahme, Birgit ^a   Siluschek, Monika ^a   Berg, Thomas ^c   Müller, Tobias ^c   Gressner, Axel M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

15 d PGJ2; Caffeine; Carcinogenesis; Chronicliver disease; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CAFFEINE; METHYLXANTHINE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ADULT; AGED; ARTICLE; CAUCASIAN; CHINESE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DRUG INDICATION; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CAFFEINE; CONNECTIVE TISSUE GROWTH FACTOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PPAR GAMMA; PROSTAGLANDIN D2; UP-REGULATION;

EID: 64749116028     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01895.x     Document Type: Article

References (47)

1. 2: A biochemical perspective. Prostaglandins Leukot Essent Fatty Acids 1989; 37: 219-34.
2. 2 in human urine. J Biol Chem 1988; 263: 16619-25.
3. 2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995; 83: 813-9.
4. Yu K, Bayona W, Kallen CB, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270: 23975-83.
5. Brun RP, Spiegelman BM. PPAR gamma and the molecular control of adipogenesis. J Endocrinol 1997; 155: 217-8.
6. Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: Ligands and activators. Ann NY Acad Sci 1996; 804: 266-75.
7. Kliewer SA, Willson TM. The nuclear receptor PPARgamma - bigger than fat. Curr Opin Genet Dev 1998; 8: 576-81.
8. Weng HL, Ciuclan L, Liu Y, et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 2007; 46: 1257-70.
9. Gressner OA, Lahme B, Siluschek M, Rehbein K, Weiskirchen R, Gressner AM. Activation of TGF-beta within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J Cell Mol Med 2008
10. Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47: 699-710.
11. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-8.
12. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002; 4: 599-604.
13. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-81.
14. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
15. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282: 23337-47.
16. Liu LY, Han YC, Wu SH, Lv ZH. Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer. World J Gastroenterol 2008; 14: 2110-4.
17. Mullis TC, Tang X, Chong KT. Expression of connective tissue growth factor (CTGF/CCN2) in head and neck squamous cell carcinoma. J Clin Pathol 2008; 61: 606-10.
18. Munemasa S, Sakai A, Kuroda Y, et al. Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is not. Br J Haematol 2007; 139: 41-50.
19. Boag JM, Beesley AH, Firth MJ, et al. High expression of connective tissue growth factor in pre-B acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 740-8.
20. Kidd M, Modlin IM, Shapiro MD, et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J Gastroenterol 2007; 13: 5208-16.
21. Hayashi N, Kakimuma T, Soma Y, et al. Connective tissue growth factor is directly related to liver fibrosis. Hepatogastroenterology 2002; 49: 133-5.
22. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26: 1-9.
23. Paradis V, Dargere D, Vidaud M, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30: 968-76.
24. George J, Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007; 14: 790-803.
25. Li G, Xie Q, Shi Y, et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006; 8: 889-900.
26. Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM. Pharmacological application of caffeine inhibits TGF-beta-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and Smad2/3-dependent pathways. J Hepatol 2008
27. Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 2006; 27: 715-23.
28. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006; 350: 385-91.
29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
30. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
31. Bioulac-Sage P, Le Bail BL, Winnock M, et al. Occurrence of hepatocellular carcinoma in nonfibrotic livers. Hepatology 2000; 32: 1411-2.
32. Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg 2008; 32: 1748-56.
33. Liver Cancer Study Group of Japan Classification of Primary Liver Cancer. Tokyo: Kanehara & Co Ltd, 1997.
34. Yamamoto T, Hirohashi K, Sakabe K, et al. Histopathological characterization of hepatocellular carcinomas which are undetected by dynamic computed tomography. Comp Hepatol 2004; 3: S56.
35. Kim YJ, Lee HS, Im JP, et al. Association of transforming growth factor-beta1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 2003; 35: 196-202.
36. Lario S, Inigo P, Campistol JM, Poch E, Rivera F, Oppenheimer F. Restriction enzyme-based method for transforming growth factor-beta(1) genotyping: Nonisotopic detection of polymorphisms in codons 10 and 25 and the 5′-flanking region. Clin Chem 1999; 45: 1290-2.
37. Birney Y, Redmond EM, Sitzmann JV, Cahill PA. Eicosanoids in cirrhosis and portal hypertension. Prostaglandins Other Lipid Mediat 2003; 72: 3-18.
38. Nunez O, Fernandez-Martinez A, Majano PL, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: Role of viral core and NS5A proteins. Gut 2004; 53: 1665-72.
39. Kitagawa T, Yokoyama Y, Kawai T, Kowai K, Watanabe K, Nagino M. The role of PPAR gamma in bile duct ligation-induced hepatic injury in rats. Hepatology 46 (Suppl. 1): 339A.
40. Poole EM, Bigler J, Whitton J, et al. Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis 2007; 28: 1259-63.
41. Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006; 154: 613-21.
42. Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005; 288: H1037-43.
43. Zhang Y, Guan Y. PPAR-gamma agonists and diabetic nephropathy. Curr Diab Rep 2005; 5: 470-5.
44. Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer 2007; 43: 1755-63.
45. Burgess HA, Daugherty LE, Thatcher TH, et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: Implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1146-53.
46. Jodynis-Liebert J, Flieger J, Matuszewska A, Juszczyk J. Serum metabolite/caffeine ratios as a test for liver function. J Clin Pharmacol 2004; 44: 338-47.
47. Gressner OA, Lahme B, Koch M, Gressner AM. Evaluation of hepatotropic targeting properties of allogenic and xenogenic erythrocyte ghosts in normal and liver-injured rats. Liver Int 2008; 28: 220-32.